Vertex Pharmaceuticals (NQ:VRTX)

524.56 -10.61 (-1.98%)

Delayed Quote Updated: 3:33 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

77 78 Next >

September 14, 2026

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...

Via StockStory

Vertex Pharmaceuticals Highlights Catalyst-Rich Pipeline Beyond Cystic Fibrosis ↗

September 12, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) highlighted a series of upcoming clinical, regulatory and commercial catalysts across renal disease, pain management, cystic fibrosis and endocrinology during a...

Via MarketBeat

Vertex Pharmaceuticals Maps Growth Beyond CF at Cantor Conference ↗

September 12, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) outlined a broadening commercial and clinical strategy at the Cantor Global Healthcare Conference, highlighting its recent Crinetics acquisition, planned renal...

Via MarketBeat

Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks

September 09, 2026

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASD...

Via StockStory

Topics Artificial Intelligence

Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock ↗

September 08, 2026

The company has tremendous prospects.

Via The Motley Fool

Topics Intellectual Property

Why CRISPR Therapeutics Stock Rocked the Market Last Month ↗

September 08, 2026

The company had fallen out of investor favor; its recovery was impressive.

Via The Motley Fool

Where Will CRISPR Therapeutics Stock Be in 5 Years? ↗

September 08, 2026

CRISPR's expanding pipeline could unlock significantly more value by 2031.

Via The Motley Fool

Replacing Insulin Cells Works. Keeping The Cells Alive Is the Trick

September 08, 2026

A look at the three approaches competing to help beta cell replacement survive the immune system

From Biotech Insider

Via GlobeNewswire

3 Market-Beating Stocks for Long-Term Investors

September 08, 2026

The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta y...

Via StockStory

Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? ↗

September 04, 2026

They could both outperform the market over the medium term, but one appears to have a clear edge.

Via The Motley Fool

Topics Intellectual Property

Here's How Much $100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth Today ↗

September 04, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.61% on an annualized basis producing an average annual return of 14.84%. Currently, Vertex Pharmaceuticals...

Via Benzinga

3 Stocks Whose Competitive Walls Tower Over Nvidia's ↗

September 03, 2026

A solid moat favors revenue growth, and that's good news for investors.

Via The Motley Fool

Topics Artificial Intelligence

2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026 ↗

September 02, 2026

We'll know a little more about the company's prospects by the end of the year.

Via The Motley Fool

Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team

September 01, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

1 S&P 500 Stock with Exciting Potential and 2 We Ignore

August 31, 2026

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...

Via StockStory

Topics Stocks

If You Invested $100 In Vertex Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today ↗

August 27, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.32% on an annualized basis producing an average annual return of 14.56%. Currently, Vertex Pharmaceuticals...

Via Benzinga

Vertex to Participate in Upcoming September Investor Conferences

August 26, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

2 Large-Cap Stocks to Research Further and 1 We Question

August 26, 2026

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it m...

Via StockStory

Inflation Is Rising Again. History Says These 2 Stocks Are Among the Smartest Places to Hide ↗

August 24, 2026

Inflation affects corporations differently. These two have the tools to navigate the challenge better than most.

Via The Motley Fool

Topics Economy Intellectual Property

Vertex Pharmaceuticals: A Biotech Cash Cow With Pipeline Upside? ↗

August 21, 2026

Vertex dominates cystic fibrosis and has a debt-free balance sheet, but can its pipeline restore faster growth? See why our analysts gave the stock a strong 7.3 out of 10.

Via The Motley Fool

CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money? ↗

August 21, 2026

This year, the biotech stock has underperformed both the Nasdaq Biotechnology Index and the S&P 500.

Via The Motley Fool

Topics ETFs Stocks

Uber, ServiceNow And A Health Care Stock On CNBC’s ‘Final Trades’ ↗

August 21, 2026

CNBC's Halftime Report Final Trades: Sechan picked ServiceNow (NYSE: NOW), Lebenthal chose Vertex (NASDAQ: VRTX) and Brown recommended Uber (NYSE: UBER).

Via Benzinga

Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead ↗

August 20, 2026

Don't bet against Vertex Pharmaceuticals in cystic fibrosis.

Via The Motley Fool

3 Cash-Producing Stocks on Our Watchlist

August 18, 2026

Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen ...

Via StockStory

Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More ↗

August 14, 2026

The drugmaker should significantly mitigate its most important risk as it develops new products.

Via The Motley Fool

$100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗

August 14, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.35% on an annualized basis producing an average annual return of 14.69%. Currently, Vertex Pharmaceuticals...

Via Benzinga

Vertex (VRTX) Q2 2026 Earnings Call Transcript ↗

August 10, 2026

Revenue hit $3.3 billion with guidance raised on strong newer product growth.

Via The Motley Fool

Topics Earnings

Discover which S&P500 stocks are making waves on Monday. ↗

August 10, 2026

Via Chartmill

Explore the top gainers and losers within the S&P500 index in today's session. ↗

August 10, 2026

Via Chartmill

Get insights into the top movers in the S&P500 index of Monday's pre-market session. ↗

August 10, 2026

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

77 78 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.